title: Prospects for the development of epigenetic drugs for CNS conditions.
abstract: Advances in our understanding of the epigenetic mechanisms that control gene expression in the central nervous system (CNS) and their role in neuropsychiatric disorders are paving the way for a potential new therapeutic approach that is focused on reversing the epigenetic underpinnings of neuropsychiatric conditions. In this article, the complexity of epigenetic processes and the current level of proof for their involvement in CNS disorders are discussed. The preclinical evidence for efficacy of pharmacological approaches that target epigenetics in the CNS and the particular challenges of this approach are also examined. Finally, strategies to address these challenges through the development of improved evidence-based epigenetic therapeutics and through combining pharmacological and behavioural approaches are presented.
authors.affiliation: Department of Pharmacology and Therapeutics, McGill University, 3655 Sir William Osler Promenade, Montreal, Canada H3G 1Y6.
authors.forename: Moshe
authors.initials: M
authors.lastname: Szyf
mesh_terms: D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000235:genetics*; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000235:genetics*; D057890:Epigenomics / Q000379:methods / Q000639:trends*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage
chemical_list: D004791:Enzyme Inhibitors; D036341:Intercellular Signaling Peptides and Proteins